Barb only Please

94366

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Donald C Jones Examiner #: 71299 Date: 19 MAY 03
Art Unit: 1614 Phone Number 30 8-1634 Serial Number: 10/056,377
Mail Box and Bldg/Room Location: 2007, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL
2007, CM1

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names): 11

Earliest Priority Filing Date: 26 JAN 2001

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the elected species of claim 4. and claim 1 and 2

****

STAFF USE ONLY		Type of Search		Vendors and cost where applicable	
Searcher:	BOB	NA Sequence (#)		STN	454
Searcher Phone #:		AA Sequence (#)		Dialog	
Searcher Location:		Structure (#)	3	Questel/Orbit	
Date Searcher Picked Up:		Bibliographic		Dr.Link	
Date Completed:	5-28-03	Litigation		Lexis/Nexis	
Searcher Prep & Review Time:	20	Fulltext		Sequence Systems	
Clerical Prep Time:		Patent Family		WWW/Internet	
Online Time:	21	Other		Other (specify)	ChemDraw

PTO-1590 (8-01)

Barb only please

94366

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Dewayne C Ivey Examiner #: 71299 Date: 19 MAY03
Art Unit: 1614 Phone Number 30 8-1634 Serial Number: 10/056,377
Mail Box and Bldg/Room Location: 2007, CM1 Results Format Preferred (circle): PAPER DISK E-MAIL
2D21, CM1

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names): 1)

Earliest Priority Filing Date: 26 JAN 2001

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search the elected species of claim 4. and claim 1 and 2

****

STAFF USE ONLY

Searcher: BOB
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: 5-28-03
Searcher Prep & Review Time: 20
Clerical Prep Time: _____
Online Time: 21

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) 3
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN 454
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) ChemDraw

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

Scientific & Technical Information Center
USPTO

STIC Database Tracking Number: 94366

TO: Dwayne C Jones **Location: mail 2D01, room 2D07** **Art Unit: 1614** **Wednesday, May 28, 2003** **Case Serial Number: 10/056397**	**From: Barb O'Bryen** **Location: Biotech-Chem Library** **CM1-6A05** **Phone: 308-4291** BOB **barbara.obryen@uspto.gov**

Search Notes

sira
Search and Information Resources Administration

BioTech-Chem Library
Search Results
Feedback Form (Optional)



Scientific & Technical Information Center

The search results generated for your recent request are attached. If you have any questions or comments (compliments or complaints) about the scope or the results of the search, please contact ***the BioTech-Chem searcher*** who conducted the search ***or contact***:

Mary Hale, Supervisor, 308-4258
CM-1 Room 1E01

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* *(Example: 1610)*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found**:*
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Search results were not useful in determining patentability or understanding the invention.

Other Comments:

Drop off completed forms at the **Circulation Desk CM-1,** or send to Mary Hale, **CM1-1E01 or e-mail mary.hale@uspto.gov.**



(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol

Caution: Stereochemical terms discarded: -

```
=> fil reg; d stat que l9
FILE 'REGISTRY' ENTERED AT 09:11:53 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAY 2003  HIGHEST RN 521262-77-1
DICTIONARY FILE UPDATES:  27 MAY 2003  HIGHEST RN 521262-77-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

L1                STR
```



OH @18

full file search done on this structure

```
VAR G1=CH2/N
VAR G2=CH/N
REP G3=(0-2) C
VPA 18-1/2/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L2            98 SEA FILE=REGISTRY SSS FUL L1
L7               STR
```



subset search done on this structure (species of clm 4)

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 31

STEREO ATTRIBUTES: NONE
L9 19 SEA FILE=REGISTRY SUB=L2 FAM FUL L7

100.0% PROCESSED 24 ITERATIONS 19 ANSWERS
SEARCH TIME: 00.00.01

=> fil capl; d que nos l19; fil uspatf; d que nos l27
FILE 'CAPLUS' ENTERED AT 09:12:02 ON 28 MAY 2003

FILE COVERS 1907 - 28 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 27 May 2003 (20030527/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1              STR
L2           98 SEA FILE=REGISTRY SSS FUL L1
L7              STR
L9           19 SEA FILE=REGISTRY SUB=L2 FAM FUL L7
L10          74 SEA FILE=CAPLUS ABB=ON  L9
L14      263709 SEA FILE=CAPLUS ABB=ON  NEOPLASM#/CW
L15      155292 SEA FILE=CAPLUS ABB=ON  ANTITUMOR AGENTS+OLD/CT
L16       74700 SEA FILE=CAPLUS ABB=ON  CARCINOMA#/OBI
L17        6794 SEA FILE=CAPLUS ABB=ON  GLIOMA#/OBI
L18          34 SEA FILE=CAPLUS ABB=ON  DESMOID TUMOR#/OBI
L19          15 SEA FILE=CAPLUS ABB=ON  L10 AND (L14 OR L15 OR L16 OR L17 OR
                L18)


FILE 'USPATFULL' ENTERED AT 09:12:02 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 May 2003 (20030527/PD)
FILE LAST UPDATED: 27 May 2003 (20030527/ED)
HIGHEST GRANTED PATENT NUMBER: US6571393
HIGHEST APPLICATION PUBLICATION NUMBER: US2003097700
CA INDEXING IS CURRENT THROUGH 27 May 2003 (20030527/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 May 2003 (20030527/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L1              STR
L2           98 SEA FILE=REGISTRY SSS FUL L1
L7              STR
L9           19 SEA FILE=REGISTRY SUB=L2 FAM FUL L7
L20          78 SEA FILE=USPATFULL ABB=ON  L9
L21       18110 SEA FILE=USPATFULL ABB=ON  NEOPLASM#/IT
L22        3248 SEA FILE=USPATFULL ABB=ON  CARCINOMA#/IT
L23         416 SEA FILE=USPATFULL ABB=ON  GLIOMA#/IT
L24           1 SEA FILE=USPATFULL ABB=ON  DESMOID/IT
```

```
L25         9868 SEA FILE=USPATFULL ABB=ON  ANTITUMOR AGENTS/CT
L26         8516 SEA FILE=USPATFULL ABB=ON  NEOPLASM INHIBITORS/CT
L27           20 SEA FILE=USPATFULL ABB=ON  L20 AND (L21 OR L22 OR L23 OR L24
                 OR L25 OR L26)


=> dup rem l19,l27
FILE 'CAPLUS' ENTERED AT 09:12:08 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:12:08 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L19
PROCESSING COMPLETED FOR L27
L35           35 DUP REM L19 L27 (0 DUPLICATES REMOVED)
                 ANSWERS '1-15' FROM FILE CAPLUS
                 ANSWERS '16-35' FROM FILE USPATFULL

=> d ibib abs hitstr l35 1-35

L35  ANSWER 1 OF 35  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2003:261603  CAPLUS
DOCUMENT NUMBER:          138:281598
TITLE:                    Androstane compounds as androgen receptor (AR)
                          modulators for the treatment of AR-related diseases
INVENTOR(S):              Wang, Jiabing
PATENT ASSIGNEE(S):       Merck & Co., Inc., USA
SOURCE:                   PCT Int. Appl., 83 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND  DATE          APPLICATION NO.  DATE
     ------------------  ----  --------      ---------------  --------
     WO 2003026568        A2   20030403      WO 2002-US29436  20020917
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     PRIORITY APPLN. INFO.:                    US 2001-324124P  P  20010921
     OTHER SOURCE(S):          MARPAT 138:281598
     GI
```



I

AB Compds. of structural formula (I) as herein defined are claimed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compds. are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, inflammatory arthritis and joint repair, alone or in combination with other active agents. Methods for the co-administration of those compds. with bone-strengthening agents are also claimed.

IT **180916-16-9**, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)

RN 180916-16-9 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 2 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:154278 CAPLUS
DOCUMENT NUMBER: 138:198670
TITLE: GnRh agonist combination drugs
INVENTOR(S): Furuya, Shuichi; Kusaka, Masami
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015820	A1	20030227	WO 2002-JP8130	20020808
JP 2003137814	A2	20030514	JP 2002-231922	20020808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: JP 2001-244616 A 20010810

AB In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination drugs characterized in that the GnRH agonist is combined with a chem. selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metab. regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.

IT **180916-16-9**, Lasofoxifene

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GnRH agonist combination drugs for treating various diseases and relieving side effects)
RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 3 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:142496 CAPLUS
DOCUMENT NUMBER: 136:194234
TITLE: Method using a rapamycin and an antiestrogen for treating estrogen receptor-positive **carcinoma**
INVENTOR(S): Zhang, Yixian; Sadler, Tammy Michelle; Frost, Philip; Greenberger, Lee Martin
PATENT ASSIGNEE(S): American Home Products Corporation, USA; Wyeth
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013802	A2	20020221	WO 2001-US24615	20010806
WO 2002013802	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001083139	A5	20020225	AU 2001-83139	20010806

US 2002045638 A1 20020418 US 2001-923217 20010806
US 6511986 B2 20030128
PRIORITY APPLN. INFO.: US 2000-224326P P 20000811
WO 2001-US24615 W 20010806

OTHER SOURCE(S): MARPAT 136:194234

AB The invention provides a method of treating or inhibiting an estrogen receptor-pos. carcinoma in a mammal in need thereof, which comprises providing the mammal with an effective amt. of a combination of a rapamycin and an antiestrogen.

IT **190791-29-8**, CP-336156
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rapamycin compd. and antiestrogen for treating estrogen receptor-pos. **carcinoma**)

RN 190791-29-8 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2 .

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



L35 ANSWER 4 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:573316 CAPLUS
DOCUMENT NUMBER: 137:119650
TITLE: Method of treating certain cancers using an estrogen agonist/antagonist
INVENTOR(S): Rosati, Robert Louis
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 43 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1226823	A2	20020731	EP 2002-250200	20020111
EP 1226823	A3	20030416		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 2001097121	A5	20020801	AU 2001-97121	20011206
JP 2002316932	A2	20021031	JP 2002-12870	20020122
CN 1366881	A	20020904	CN 2002-102519	20020125

PRIORITY APPLN. INFO.: US 2001-264566P P 20010126
OTHER SOURCE(S): MARPAT 137:119650

AB The invention provides methods of treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma using an estrogen agonist/antagonist. The invention also provides kits that contain an estrogen agonist/antagonist for treating cancer of the liver, ovarian cancer, a desmoid tumor, glioma, pancreatic cancer, or renal cell carcinoma.

IT **180915-78-0 180915-78-0D**, derivs. **252863-41-5**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonist/antagonist for cancer treatment)

RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 252863-41-5 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0
CMF C28 H31 N O2

Relative stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



L35 ANSWER 5 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:762983 CAPLUS
DOCUMENT NUMBER: 135:303769
TITLE: Preparation of estrogen agonist/antagonist metabolites
INVENTOR(S): Day, Wesley Warren; Johnson, Kim Anne; Prakash, Chandra Aggarwal; Eggler, James Frederick
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077093	A1	20011018	WO 2001-IB427	20010319
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1268453	A1	20030102	EP 2001-912069	20010319
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009838	A	20030121	BR 2001-9838	20010319
US 2002042443	A1	20020411	US 2001-825980	20010404
US 6455572	B2	20020924		
NO 2002004767	A	20021203	NO 2002-4767	20021003

PRIORITY APPLN. INFO.: US 2000-267198P P 20000407
WO 2001-IB427 W 20010319

OTHER SOURCE(S): MARPAT 135:303769
GI



I

AB This invention relates to compds. represented by formula [I; R1 = pyrrolidin-1-yl, 2-oxopyrrolidin-1-yl, 2-hydroxy-1-pyrrolidin-1-yl, 2-methoxy-1-pyrrolidin-1-yl, NH(CH2)3COR6 (where R6 = OH, NHCH2CO2H); R2, R3, R4, R7 = H, OH, OMe; provided that (a) if R1 is pyrrolidin-1-yl or NH(CH2)3CO2H, and (b) R2 is OH or OMe and R3 and R7 are H, or if R1 is defined in (a) and (c) R2 and R7 are H and R3 is OH or OMe, then R4 is not H] which are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol (PPTN) and are believed to possess significant pharmacol. activities similar or identical to those possessed by the parent PPTN. The compds. of the invention can be used as stds. for anal. assays or as intermediates for the further chem. synthesis or biosynthesis of chem. entities. The invention also relates to pharmaceutical compns. for the treatment of disease and methods of treating disease. Examples of diseases or conditions for which the compds. can be effective include osteoporosis, breast cancer, hyperlipidemia, atherosclerosis, Alzheimer's disease, cataracts, loss of libido, male sexual dysfunction, colon cancer, skin wrinkles, autoimmune disease, alopecia, acne, cardiovascular disease, cataracts, diabetes, endometriosis, female sexual dysfunction, hyperglycemia, obesity, obsessive compulsive disorder, etc. (no data). Thus, 1-[2-[4-(2-Bromo-6,7-dimethoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine was coupled with phenylboronic acid in the presence of tetrakis(triphenylphosphine)pal ladium and Na2CO3 in EtOH at room temp. for 10 h to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine which was hydrogenated Pd(OH)2 on carbon in a mixt. of 2 N aq. HCl, H2O, and EtOH at 50.degree. under a H atm. of 30 psi to give 1-[2-[4-(6,7-dimethoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine. The latter compd. was heated in a mixt. of AcOH and 48% aq. HBr at 90.degree. for 2 h to give cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2,3-diol and a mixt. of cis-3-methoxy-7-phenyl-8-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and cis-3-methoxy-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol.

IT **180916-16-9**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(animal metab.; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

RN 180916-16-9 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **366470-00-0P 366470-01-1P**
RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(metabolite in mice; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)

RN 366470-00-0 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-ar-methoxy-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)



D1—O—Me

RN 366470-01-1 CAPLUS

CN ar,2-Naphthalenediol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)



D1—OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 6 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:564841 CAPLUS
DOCUMENT NUMBER: 135:132470
TITLE: Selective estrogen receptor modulators in combination with estrogens for therapeutic use
INVENTOR(S): Labrie, Fernand
PATENT ASSIGNEE(S): Endorecherche, Inc., Can.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001054699	A1	20010802	WO 2001-CA86	20010126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1251855	A1	20021030	EP 2001-902194	20010126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008107	A	20030311	BR 2001-8107	20010126
US 2002198179	A1	20021226	US 2001-52803	20011107
US 2003040510	A1	20030227	US 2001-52824	20011107
US 2003065008	A1	20030403	US 2002-143894	20020509
NO 2002003484	A	20020722	NO 2002-3484	20020722
PRIORITY APPLN. INFO.:			US 2000-178601P P	20000128

Searched by Barb O'Bryen, STIC 308-4291

US 2001-771180 A1 20010126
WO 2001-CA86 W 20010126

OTHER SOURCE(S): MARPAT 135:132470

GI



I

AB Methods for redn. or elimination of the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals, including humans, involves administration of selective estrogen receptor modulators, particularly compds. I (R1, R2 = OH, moiety convertible to OH in vivo; R3 = (un)satd. (substituted) pyrrolidinyl, (un)satd. (substituted) piperidinyl, etc.) and an amt. of an estrogen or mixed estrogenic/androgenic compd. Further administration of bisphosphonates, or a sex steroid precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compns. for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

IT **180916-16-9**, Lasofoxifene
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulators in combination with estrogens for therapeutic use)

RN 180916-16-9 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 7 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:796237 CAPLUS
DOCUMENT NUMBER: 135:344497
TITLE: Synthesis and use of pyrazolo-pyrimidines as estrogen agonists/antagonists for treating female sexual dysfunction
INVENTOR(S): Lee, Andrew George; Thompson, David Duane; Day, Wesley Warren
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 47 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1149579	A2	20011031	EP 2001-303481	20010412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002013327	A1	20020131	US 2001-833169	20010411
CA 2344090	AA	20011018	CA 2001-2344090	20010412
JP 2001302547	A2	20011031	JP 2001-117990	20010417
NZ 511131	A	20021126	NZ 2001-511131	20010417

PRIORITY APPLN. INFO.: US 2000-266387P P 20000418
OTHER SOURCE(S): MARPAT 135:344497
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = CH2, NR; X, D, E = CH, N; Y = Ph, naphthyl, cycloalk(en)yl, heterocyclyl, etc.; Z1 = alkyl, alkyloxy, alkylamino, etc.; G = amino; R = H, alkyl; n = 0 - 2] were prepd. For example, 4-amino-3-ethyl-1H-pyrazole-5-carboxamide was condensed with

3-carboxy-2-ethoxy-5-(4-ethylpiperazin-1-ylsulfonyl)pyridine (prepn. given, DMF, HOBt, Et3N, EDCI, room temp., 6 h). The pyrazole moiety of the resulting adduct was N-alkylated (DMF, Cs2CO3, Br(CH2)2OMe, 60.degree.C, 18 h) and cyclized to pyrazolo[4,3-d]pyrimidine II (EtOH, EtOAc, KHMDS, 120.degree.C, 12 h). I are estrogen receptor agonists/antagonists and when co-administered with a cyclic 3',5'-guanosine monophosphate elevator, are used to treat (e.g.) hypoactive sexual desire disorder, sexual arousal disorder, etc.

IT **351527-09-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis and use of pyrazolo-pyrimidines as estrogen agonists/antagonists for treating female sexual dysfunction)

RN 351527-09-8 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 8 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:559558 CAPLUS
DOCUMENT NUMBER: 135:142234
TITLE: Compositions and methods for treating conditions responsive to estrogen
INVENTOR(S): Thompson, David Duane; Lee, Andrew George; Day, Wesley Warren; Rosati, Robert Louis
PATENT ASSIGNEE(S): ~~Pfizer Products Inc.~~, USA
SOURCE: Eur. Pat. Appl., 36 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1120114	A2	20010801	EP 2001-300221	20010111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001041718	A1	20011115	US 2001-758778	20010111
NZ 509321	A	20021025	NZ 2001-509321	20010111

JP 2001213776 A2 20010807 JP 2001-4452 20010112
PRIORITY APPLN. INFO.: US 2000-175752P P 20000112
OTHER SOURCE(S): MARPAT 135:142234

AB This invention relates to methods, pharmaceutical compns. and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compns. include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration. The in vitro antiproliferative effects of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol were tested in 2 types of human breast cancer cell lines: first, MCF-7 cells, which contain ER as well as progesterone receptors (PgR), and second, MDA-MB-231 cells, which lack ER and PgR, and enable the detn. of an effect that is independent of the ER mechanism. Growth inhibition was ER-specific and not due to cytotoxicity since the compd. had no measurable effect on the ER-neg. cell line.

IT **180915-78-0 180916-16-9 351527-09-8**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treating conditions responsive to estrogen)

RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351527-09-8 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 9 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:541600 CAPLUS
DOCUMENT NUMBER: 135:117261
TITLE: Method using estrogen agonists/antagonists for reducing morbidity and the risk of mortality from cardiovascular disease, breast cancer, and osteoporosis
INVENTOR(S): Day, Wesley Warren; Lee, Andrew George; Thompson, David Duane
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 37 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English

Searched by Barb O'Bryen, STIC 308-4291

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1118323	A2	20010725	EP 2001-300159	20010109
EP 1118323	A3	20030521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2001056099	A1	20011227	US 2001-757817	20010110
JP 2001226265	A2	20010821	JP 2001-5300	20010112

PRIORITY APPLN. INFO.: US 2000-175663P P 20000112
OTHER SOURCE(S): MARPAT 135:117261

AB The invention discloses methods, pharmaceutical compns., and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined redn. of breast cancer, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compns. are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier, or diluent. The compns. and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects assocd. with estrogen administration.

IT **180916-16-9**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and osteoporosis)

RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180915-78-0** **180915-78-0D**, isomers, N-oxides, esters, and prodrug derivs. **180916-16-9D**, isomers, N-oxides, esters, and prodrug derivs. **351194-06-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen agonists/antagonists for reducing morbidity and risk of

mortality from cardiovascular disease, breast cancer, and osteoporosis)
RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351194-06-4 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



L35 ANSWER 10 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:12736 CAPLUS
DOCUMENT NUMBER: 136:226440
TITLE: LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model
AUTHOR(S): Cohen, Leonard A.; Pittman, Brian; Wang, Chung-Xiou; Aliaga, Cesar; Yu, Li; Moyer, James D.
CORPORATE SOURCE: American Health Foundation, Valhalla, NY, 10595, USA
SOURCE: Cancer Research (2001), 61(24), 8683-8688
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The N-nitroso-N-methylurea-induced rat mammary tumor model was used to conduct two types of studies: a prevention study designed to test the ability of the novel selective estrogen receptor modulator lasofoxifene (LAS) to inhibit the development of mammary tumors, and a treatment study designed to test the inhibitory effect of LAS on the growth of established tumors. The prevention study indicated that LAS markedly delayed the emergence of N-nitroso-N-methylurea-induced tumors to an extent similar to that obtained by the established antiestrogen tamoxifen (TAM). At the highest dose administered, both TAM and LAS reduced tumor incidence by 75% and total tumor no. by 90% relative to the controls. LAS also reduced the multiplicity of tumors, i.e., the mean no. of tumors per rat, and resulted in substantially smaller total tumor burden. In the treatment study, LAS significantly inhibited tumor growth compared with the controls. In addn., whereas none of the untreated tumors regressed completely over the exptl. period, 40% of LAS-treated tumors regressed by >50% at the highest dose (10 mg/kg daily). The results of this study in a rat mammary tumor model indicate that LAS has both chemopreventive and chemotherapeutic effects quant. comparable with those of TAM.

IT **180916-16-9**, Lasofoxifene
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor activity of lasofoxifene in N-nitroso-N-methylurea-induced rat mammary tumor model)

RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 11 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:647817 CAPLUS
DOCUMENT NUMBER: 135:366221
TITLE: Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer
AUTHOR(S): Dhingra, Kapil
CORPORATE SOURCE: Hoffmann-La Roche, Inc., Nutley, NJ, 07110, USA
SOURCE: Cancer Investigation (2001), 19(6), 649-659
CODEN: CINVD7; ISSN: 0735-7907
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with refs. Female hormones, esp. estrogens, play an important role in the pathogenesis of breast neoplasms and are a principal determinant of their biol. behavior. Endocrine manipulation through medical or surgical means can often lead to objective shrinkage of breast tumors. Tamoxifen, a triphenylethylene estrogen receptor modulator, is currently the most widely used hormonal treatment for breast cancer. It has been conclusively demonstrated to reduce the risk of relapse following definitive local therapy (and systemic chemotherapy, when indicated) of invasive or non-invasive breast cancer. Recently, it has also been shown to reduce the incidence of breast cancer in healthy women who are at high risk of developing the disease. In addn., it can prevent osteoporosis and reduce the risk of fractures in postmenopausal women. However, its use is also complicated by an increased incidence of endometrial hyperplasia/carcinoma, venous thromboembolism, cataracts, and in some cases, emergence of tamoxifen-dependent clones of breast cancer. These side effects (except cataracts) are believed to be related to estrogen-agonist effects of tamoxifen. Newer drugs, which are "pure antiestrogens" or inhibitors of estrogen biosynthesis, are devoid of such estrogen-agonist activity and may not have the liability of many of these side effects. However, these agents would also be expected to lack the potentially beneficial effects of tamoxifen on lipids and skeletal system. The ability of tamoxifen to act as an estrogen-agonist or estrogen-antagonist in a tissue-specific fashion has led to the concept of selective estrogen-receptor modulation. Selective estrogen receptor modulators (SERMs), which are devoid of estrogen-agonist effects on the uterus or breast cancer cells but retain potentially beneficial effects on

bones and lipids, have been described as "ideal" SERMs. A no. of such compds. are currently being tested. Raloxifene is already approved for prevention of osteoporosis and has potential efficacy for prevention and treatment of breast cancer. An analog of raloxifene, LY353381, is currently in Phase II clin. trials for treatment of breast cancer, with promising early results. EM800 and CP336156 are other promising ideal SERMs in clin. trials. These compds. may provide better treatment and chemoprevention alternatives for breast cancer as compared to tamoxifen, aromatase inhibitors, and pure antiestrogens. In addn., they may also prove to be useful for the treatment and prevention of prostate cancer as well as for treating benign gynecol. diseases such as fibroids and endometriosis. Future lab. efforts should focus on further broadening the efficacy profile of SERMs (e.g., prevention of Alzheimer's disease and elevation of high-d. lipoproteins to improve the likelihood of cardiovascular benefit) and narrowing their side-effect profile (e.g., risk of thromboembolism and hot flashes).

IT **190791-29-8**, CP336156
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulation in hormonal therapy for breast cancer in humans)

RN 190791-29-8 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 12 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:892995 CAPLUS
DOCUMENT NUMBER: 135:28546
TITLE: Other selective estrogen receptor modulators (SERMs) in development
AUTHOR(S): Neven, P.
CORPORATE SOURCE: Algemene Kliniek St-Jan, Brussels, B-1000, Belg.
SOURCE: European Journal of Cancer (2000), 36(Suppl. 4), S65-S66
CODEN: EJCAEL; ISSN: 0959-8049
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review with 7 refs. Other new compds. in development are GW 5638 (a triphenylethylene) and lasofoxifene or CP-336,156, already referred to as SERM IV. Both appear, at least in the rat model, to have a markedly reduced uterotropic effect while maintaining tamoxifen's beneficial activities on bone, lipids and breast. SCH 57050, a benzopyran, has potent anti-estrogenic characteristics in MCF-7 human breast cancer cells and it also prevents the development of dimethylbenz(a)anthracene-induced mammary tumors.

IT **190791-29-8**, CP-336156
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen receptor modulators in development)

RN 190791-29-8 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 13 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:414063 CAPLUS
DOCUMENT NUMBER: 127:34119
TITLE: Preparation of (-)-cis-(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate by optical resolution
INVENTOR(S): Chiu, Charles K.; Meltz, Morgan
PATENT ASSIGNEE(S): Pfizer Inc., USA; Chiu, Charles K.; Meltz, Morgan
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9716434	A1	19970509	WO 1996-IB1049	19961004

W: AU, BG, BR, BY, CA, CN, CZ, HU, IL, IS, JP, KR, KZ, LK, LV, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US, UZ, VN
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,

SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

CA 2236673	AA	19970509	CA 1996-2236673	19961004	
AU 9669984	A1	19970522	AU 1996-69984	19961004	
AU 708841	B2	19990812			
EP 876359	A1	19981111	EP 1996-931206	19961004	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LV, FI					
CN 1201458	A	19981209	CN 1996-198048	19961004	
CN 1067065	B	20010613			
JP 11502866	T2	19990309	JP 1996-517180	19961004	
BR 9611436	A	19990323	BR 1996-11436	19961004	
JP 3088020	B2	20000918	JP 1997-517180	19961004	
CZ 287341	B6	20001011	CZ 1998-1320	19961004	
RU 2162465	C2	20010127	RU 1998-110128	19961004	
IL 124027	A1	20011031	IL 1996-124027	19961004	
SK 282172	B6	20011106	SK 1998-542	19961004	
ZA 9609212	A	19980504	ZA 1996-9212	19961101	
US 5948809	A	19990907	US 1998-65094	19980428	
NO 9801962	A	19980430	NO 1998-1962	19980430	

PRIORITY APPLN. INFO.: US 1995-6125P P 19951102
WO 1996-IB1049 W 19961004

GI



I

AB An advantageous process for the prepn. of (-)-cis-(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol [(5R,6S)-I] D-tartrate involves dissolving racemic or partially optically enriched I in boiling aq. ethanol to form a soln., adding an equal molar amt. of D-tartaric acid in aq. ethanol to above soln. to form a second soln., cooling the second soln., and collecting (5R,6S)-I D-tartrate. A method for treating osteoporosis, cardiovascular disease or hyperlipidemia, prostatic disease, obesity, breast cancer, or endometriosis or for lowering serum cholesterol level in an mammal comprises administering (5R,6S)-I D-tartrate to a mammal. Thus, 1-[2-[4-(2-bromo-6-methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine was coupled with phenylboronic acid in the presence of (Ph3P)4Pd and Na2CO3 in THF under reflux for 2 h to give 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine hydrochloride (nafoxidine hydrochloride), which was hydrogenated over Pd(OH)2 in MeOH/EtOH at 50.degree. and 50 psi for 68 h to give cis-1-[2-[4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine. This was heated in a mixt. of HBr and AcOH at 100.degree. for 15 h followed by treating the hydrobromide salt in CHCl3/MeOH with satd. NaHCO3 soln. to give racemic I. Racemic I (5 g) in a 95:5 mixt. of abs. ethanol/H2O (50 mL) was treated with a soln. of 1.83 g D-tartaric acid in a 95:5 mixt. of abs. ethanol/H2O (20 mL) and heated under gentle reflux to give a homogeneous soln., which was cooled and stirred at ambient temp. (.apprx.25.degree.) overnight.

The salt pptd. out as a white solid, collected by suction filtration, washed with 20 mL abs. ethanol, and dried under vacuum to give 2.77 g (5R,6S)-I, which was recrystd. from the same solvent to give 2.48 g (5R,6S)-I with an optical purity of >99.1%. (5R,6S)-I D-tartrate was administered to rats by s.c. injection to decrease prostate wt.

IT **180915-78-0P 180915-90-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of (-)-cis-(5R,6S)-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydro naphthalen-2-ol D-tartrate by optical resoln. for disease treatment)

RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-90-6 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **190791-29-8P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (-)-cis-(5R,6S)-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydro naphthalen-2-ol D-tartrate by optical resoln. for disease treatment)
RN 190791-29-8 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



L35 ANSWER 14 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1997:600450 CAPLUS
DOCUMENT NUMBER: 127:243267
TITLE: Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S): MacLean, David B.; Thompson, David D.
PATENT ASSIGNEE(S): Pfizer Inc., USA

Searched by Barb O'Bryen, STIC 308-4291

SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 792641	A1	19970903	EP 1997-301147	19970221
EP 792641	B1	20010801		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 6107331	A	20000822	US 1997-803733	19970221
EP 1106179	A2	20010613	EP 2001-101953	19970221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 203670	E	20010815	AT 1997-301147	19970221
ES 2159811	T3	20011016	ES 1997-301147	19970221
CA 2198578	AA	19970828	CA 1997-2198578	19970226
CA 2198578	C	20020611		
ZA 9701714	A	19970827	ZA 1997-1714	19970227
AU 9714979	A1	19970904	AU 1997-14979	19970227
AU 703473	B2	19990325		
CN 1167617	A	19971217	CN 1997-103414	19970228
JP 10007563	A2	19980113	JP 1997-45652	19970228
US 6274618	B1	20010814	US 1999-314758	19990519
US 6355670	B1	20020312	US 2000-511806	20000223
US 2001018451	A1	20010830	US 2001-803516	20010309
US 6403611	B2	20020611		
US 2002091121	A1	20020711	US 2001-999291	20011115

PRIORITY APPLN. INFO.:
US 1996-13212P P 19960228
EP 1997-301147 A3 19970221
US 1997-803733 A1 19970221
US 1999-314758 A1 19990519
US 2000-511806 A3 20000223

OTHER SOURCE(S): MARPAT 127:243267

AB Estrogen antagonists or agonists such as cis-6-(4-fluorophenyl)-5-[4-(2-piperidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol are used to treat pathol. conditions such as breast disorder, vaginal atrophy, bladder infection, etc.

IT **180915-78-0 180916-16-9**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180915-78-0 CAPLUS

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 15 OF 35 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1996:551346 CAPLUS
DOCUMENT NUMBER: 125:195446
TITLE: Preparation of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists
INVENTOR(S): Cameron, Kimberly O.; Jardine, Paul A. DaSilva
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

Searched by Barb O'Bryen, STIC 308-4291

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9621656	A1	19960718	WO 1995-IB286	19950424
W: CA, FI, JP, MX, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5552412	A	19960903	US 1995-369954	19950109
CA 2209925	AA	19960718	CA 1995-2209925	19950424
EP 802910	A1	19971029	EP 1995-914493	19950424
EP 802910	B1	20020313		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
JP 10503215	T2	19980324	JP 1995-521528	19950424
JP 2972347	B2	19991108		
EP 1151998	A1	20011107	EP 2001-120246	19950424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
AT 214382	E	20020315	AT 1995-914493	19950424
ES 2172579	T3	20021001	ES 1995-914493	19950424
SK 281992	B6	20010911	SK 1995-1648	19951222
IL 116643	A1	20000813	IL 1996-116643	19960101
IL 130761	A1	20001206	IL 1996-130761	19960101
RU 2130454	C1	19990520	RU 1996-100074	19960105
NO 9600081	A	19960710	NO 1996-81	19960108
CN 1136562	A	19961127	CN 1996-100634	19960108
CN 1059902	B	20001227		
LV 11460	B	19961220	LV 1996-4	19960108
ZA 9600095	A	19970708	ZA 1996-95	19960108
CZ 285085	B6	19990512	CZ 1996-55	19960108
PL 183474	B1	20020628	PL 1996-312182	19960108
AU 9640916	A1	19960718	AU 1996-40916	19960109
AU 700982	B2	19990114		
BR 9600079	A	19980127	BR 1996-79	19960109
US 6204286	B1	20010320	US 1997-849726	19970630
FI 9702903	A	19970708	FI 1997-2903	19970708
US 6153622	A	20001128	US 1998-141613	19980828
US 6441193	B1	20020827	US 1999-466034	19991217
US 2001025051	A1	20010927	US 2001-820158	20010328
US 2002132816	A1	20020919	US 2002-147725	20020516

PRIORITY APPLN. INFO.:			
US 1995-369954	A1	19950109	
EP 1995-914493	A3	19950424	
WO 1995-IB286	W	19950424	
IL 1996-116643	A3	19960101	
US 1997-849726	A1	19970630	
US 1999-466034	A1	19991217	

OTHER SOURCE(S): MARPAT 125:195446
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; A = CH2, (substituted) NH; B, D, E = CH, N; Y = (substituted) Ph, naphthyl, C3-8 cycloalkyl, etc.; Z1 = (substituted) SCH2CH2, OCH2CH2, etc.; G = (substituted) NH2, pyrrolidino, piperidino, etc.; e = 0-2], useful for treating or preventing obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia and prostatic disease, were prepd. Thus, hydrogenation of nafoxidene.HCl (II.HCl) over palladium hydroxide/C in EtOH followed by treatment of the intermediate cis-III with BBr3/CH2Cl2 afforded cis-I [A = CH2; B, D, E = CH; Y = Ph; Z1 = OCH2CH2; G = pyrrolidino; e = 1; 2-OH]. Compds. I

significantly ($P < 0.05$) decreased prostate wt. compared to control in male Sprague-Dawley rats.

IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)

RN 180915-78-0 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-91-7 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-93-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 CAPLUS
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0
CMF C28 H31 N O2

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P



L35 ANSWER 16 OF 35 USPATFULL
ACCESSION NUMBER: 2003:93647 USPATFULL
TITLE: Selective estrogen receptor modulators in combination with estrogens
INVENTOR(S): Labrie, Fernand, Sainte-foy, CANADA
PATENT ASSIGNEE(S): Endorecherche, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065008	A1	20030403
APPLICATION INFO.:	US 2002-143894	A1	20020509 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-771180, filed on 26 Jan 2001, PENDING

NUMBER	DATE

PRIORITY INFORMATION: US 2000-178601P 20000128 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403
NUMBER OF CLAIMS: 48
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 3036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator, particularly compounds having the general structure ##STR1##

and an amount of an estrogen or mixed estrogenic/androgenic compound. Further administration of bisphosphonates, or sex steroid precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180916-16-9**, Lasofoxifene
(selective estrogen receptor modulators in combination with estrogens for therapeutic use)
RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 17 OF 35 USPATFULL
ACCESSION NUMBER: 2003:57944 USPATFULL
TITLE: Selective estrogen receptor modulators in combination with estrogens

INVENTOR(S): Labrie, Fernand, Sainte-foy, CANADA
PATENT ASSIGNEE(S): Endorecherche, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003040510	A1	20030227
APPLICATION INFO.:	US 2001-52824	A1	20011107 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-771180, filed on 26 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178601P	20000128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 2854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator, particularly compounds having the general structure: ##STR1##

and an amount of an estrogen or mixed estrogenic/androgenic compound. Further administration of bisphosphonates, or sex steroid precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180916-16-9**, Lasofoxifene
(selective estrogen receptor modulators in combination with estrogens for therapeutic use)
RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 18 OF 35 USPATFULL
ACCESSION NUMBER: 2002:344449 USPATFULL
TITLE: Selective estrogen receptor modulators in combination with estrogens
INVENTOR(S): Labrie, Fernand, Sainte-foy, CANADA
PATENT ASSIGNEE(S): Endorecherche, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198179	A1	20021226
APPLICATION INFO.:	US 2001-52803	A1	20011107 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-771180, filed on 26 Jan 2001, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178601P	20000128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: OSTROLENK FABER GERB & SOFFEN, 1180 AVENUE OF THE AMERICAS, NEW YORK, NY, 100368403
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 34 Drawing Page(s)
LINE COUNT: 3044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel methods for reduction or elimination the incidence of hot flashes and menopausal symptoms, while decreasing the risk of acquiring breast or endometrial cancer and furthermore treating and/or inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes, loss of muscle mass, obesity, irregular menstruation, Alzheimer's disease, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator, particularly compounds having the general structure: ##STR1##

and an amount of an estrogen or mixed estrogenic/androgenic compound. Further administration of bisphosphonates, or sex steroid precursor is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical

compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180916-16-9**, Lasofoxifene
(selective estrogen receptor modulators in combination with estrogens for therapeutic use)
RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 19 OF 35 USPATFULL
ACCESSION NUMBER: 2002:243625 USPATFULL
TITLE: Estrogen agonists/antagonists for preventing breast cancer
INVENTOR(S): Cameron, Kimberly O., East Lyme, CT, UNITED STATES
Dasilva-Jardine, Paul A., Rhode Island, CT, UNITED STATES
Ke, Hua Zhu, Ledyard, CT, UNITED STATES
Rosati, Robert L., Stonington, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132816	A1	20020919
APPLICATION INFO.:	US 2002-147725	A1	20020516 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-466034, filed on 17 Dec 1999, PENDING Continuation of Ser. No. US 1997-849726, filed on 30 Jun 1997, GRANTED, Pat. No. US 6204286 A 371 of International Ser. No. WO 1995-IB286, filed on 24 Apr 1995, UNKNOWN Continuation of Ser. No. US 1995-369954, filed on 9 Jan 1995, PATENTED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of this formula ##STR1##

are useful for preventing breast cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180915-78-0P 180915-79-1P 180915-85-9P**
180915-90-6P 180915-91-7P 180915-93-9P
180916-16-9P
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



L35 ANSWER 20 OF 35 USPATFULL
ACCESSION NUMBER: 2002:172363 USPATFULL
TITLE: Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S): MacLean, David B., Providence, RI, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002091121	A1	20020711
APPLICATION INFO.:	US 2001-999291	A1	20011115 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 2000-511806, filed on 23 Feb 2000, PATENTED Division of Ser. No. US 1997-803733, filed on 21 Feb 1997, PATENTED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13212P	19960228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Paten Department, MS 4159, Easter Point Road, Groton, CT, 06340	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2060	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0 180916-16-9**
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 21 OF 35 USPATFULL
ACCESSION NUMBER: 2002:85594 USPATFULL
TITLE: Method of treating estrogen receptor positive carcinoma
INVENTOR(S): Zhang, Yixian, Nanuet, NY, UNITED STATES
Sadler, Tammy M., Chester, NY, UNITED STATES
Frost, Philip, Morris Township, NJ, UNITED STATES
Greenberger, Lee Martin, Montclair, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002045638	A1	20020418	
	US 6511986	B2	20030128	
APPLICATION INFO.:	US 2001-923217	A1	20010806	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-224326P	20000811	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, American Home Products Corporation, Patent Law Department - 2B, Five Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **190791-29-8**, CP-336156
(rapamycin compd. and antiestrogen for treating estrogen receptor-pos. **carcinoma**)
RN 190791-29-8 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6
CDES 1:S2:R*,R*

Absolute stereochemistry.



L35 ANSWER 22 OF 35 USPATFULL

ACCESSION NUMBER:	2002:78785 USPATFULL		
TITLE:	Estrogen agonist / antagonist metabolites		
INVENTOR(S):	Day, Wesley W., Old Lyme, CT, UNITED STATES		
	Johnson, Kim A., East Haven, CT, UNITED STATES		
	Prakash, Chandra A., Gales Ferry, CT, UNITED STATES		
	Eggler, James F., Stonington, CT, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002042443	A1	20020411	
	US 6455572	B2	20020924	
APPLICATION INFO.:	US 2001-825980	A1	20010404	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-267198P	20000407 (60)

Searched by Barb O'Bryen, STIC 308-4291

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 1310
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compounds that are mammalian metabolites of (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates for the further chemical synthesis or biosynthesis of chemical entities. The invention also relates to pharmaceutical compositions for the treatment of disease and methods of treating disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180916-16-9**
(animal metab.; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)
RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **366470-00-0P 366470-01-1P**
(metabolite in mice; prepn. of metabolites of (-)-cis-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalenol estrogen agonist/antagonist as therapeutic agents)
RN 366470-00-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-ar-methoxy-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)



D1—O—Me

RN 366470-01-1 USPATFULL
CN ar,2-Naphthalenediol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)



D1--OH

L35 ANSWER 23 OF 35 USPATFULL
ACCESSION NUMBER: 2002:22491 USPATFULL
TITLE: Compositions and methods for treating female sexual dysfunction
INVENTOR(S): Lee, Andrew G., Old Lyme, CT, UNITED STATES
Thompson, David D., Gales Ferry, CT, UNITED STATES
Day, Wesley W., Old Lyme, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013327	A1	20020131
APPLICATION INFO.:	US 2001-833169	A1	20010411 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-266387P	20000418 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods, pharmaceutical compositions and kits useful in treating female sexual dysfunction and the use of an estrogen agonist/antagonist for the manufacture of a medicament for the treatment of female sexual dysfunction. The compositions are comprised of an estrogen agonist/antagonist as a first active ingredient and a cyclic guanosine 3',5'-monophosphate elevator as a second active component and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **351527-09-8**
(synthesis and use of pyrazolo-pyrimidines as estrogen agonists/antagonists for treating female sexual dysfunction)
RN 351527-09-8 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 24 OF 35 USPATFULL
ACCESSION NUMBER: 2002:217426 USPATFULL
TITLE: Estrogen agonists/antagonists
INVENTOR(S): Cameron, Kimberly O., East Lyme, CT, United States

Dasilva-Jardine, Paul A., Providence, CT, United States
Ke, Hua Zhu, Ledyard, CT, United States
Rosati, Robert L., Stonington, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6441193	B1	20020827
APPLICATION INFO.:	US 1999-466034		19991217 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 849726, now patented, Pat. No. US 6204286 Continuation of Ser. No. US 1995-369954, filed on 9 Jan 1995, now patented, Pat. No. US 5552412
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pryor, Alton
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Crissey, Todd M.
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 1335

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of this formula ##STR1##

are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)-. (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



L35 ANSWER 25 OF 35 USPATFULL

ACCESSION NUMBER:	2002:51000 USPATFULL
TITLE:	Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S):	Maclean, David B., Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States
PATENT ASSIGNEE(S):	Pfizer, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6355670	B1	20020312
APPLICATION INFO.:	US 2000-511806		20000223 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997		

Searched by Barb O'Bryen, STIC 308-4291

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13212P	19960228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Goldberg, Jerome D.	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Crissey, Todd M.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	2011	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0 180916-16-9**
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 26 OF 35 USPATFULL
ACCESSION NUMBER: 2001:237979 USPATFULL
TITLE: Method of reducing morbidity and the risk of mortality
INVENTOR(S): Day, Wesley W., Old Lyme, CT, United States
Lee, Andrew G., Old Lyme, CT, United States
Thompson, David D., Gales Ferry, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001056099	A1	20011227
APPLICATION INFO.:	US 2001-757817	A1	20010110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175663P	20000112 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1997
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods, pharmaceutical compositions and kits useful in reducing cardiovascular morbidity and the risk of mortality in men and post-menopausal women and morbidity and the risk of mortality in post-menopausal women from the combined reduction of breast cancer, osteoporosis and cardiovascular disease by the administration of estrogen agonists/antagonists. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180916-16-9**
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and osteoporosis)
RN 180916-16-9 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180915-78-0 180915-78-0D**, isomers, N-oxides, esters, and prodrug derivs. **180916-16-9D**, isomers, N-oxides, esters, and prodrug derivs. **351194-06-4**
(estrogen agonists/antagonists for reducing morbidity and risk of mortality from cardiovascular disease, breast cancer, and osteoporosis)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351194-06-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (2:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6
CDES 1:S2:R*,R*

Absolute stereochemistry.



L35 ANSWER 27 OF 35 USPATFULL

ACCESSION NUMBER:	2001:205925 USPATFULL
TITLE:	Compositions and methods for treating conditions responsive to estrogen
INVENTOR(S):	Thompson, David D., Gales Ferry, CT, United States Lee, Andrew G., Old Lyme, CT, United States Day, Wesely W., Old Lyme, CT, United States Rosati, Robert L., Stonington, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041718	A1	20011115
APPLICATION INFO.:	US 2001-758778	A1	20010111 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175752P	20000112 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS:	31
EXEMPLARY CLAIM:	1

NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 2385
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods, pharmaceutical compositions and kits useful in treating conditions responsive to estrogen by the administration of estrogen agonists/antagonists. Conditions responsive to the compositions and methods include rheumatoid arthritis, colon cancer, tissue wounds, skin wrinkles and cataracts. The compositions are comprised of an estrogen agonist/antagonist and a pharmaceutically acceptable vehicle, carrier or diluent. The compositions and methods of treatment are effective while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180915-78-0 180916-16-9 351527-09-8**
(compns. for treating conditions responsive to estrogen)
RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 351527-09-8 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



L35 ANSWER 28 OF 35 USPATFULL
ACCESSION NUMBER: 2001:165841 USPATFULL
TITLE: Estrogen agonists/antagonists for preventing breast cancer
INVENTOR(S): Cameron, Kimberly O., East Lyme, CT, United States
Dasilva-Jardine, Paul A., Providence, RI, United States
Ke, Hua Zhu, Ledyard, CT, United States
Rosati, Robert L., Stonington, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001025051	A1	20010927
APPLICATION INFO.:	US 2001-820158	A1	20010328 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-466034, filed on 17

Searched by Barb O'Bryen, STIC 308-4291

Dec 1999, PENDING Continuation of Ser. No. US 1997-849726, filed on 30 Jun 1997, GRANTED, Pat. No. US 6204286 A 371 of International Ser. No. WO 1995-IB286, filed on 24 Apr 1995, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1388
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of this formula ##STR1##

are useful for preventing breast cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



L35 ANSWER 29 OF 35 USPATFULL

ACCESSION NUMBER:	2001:145314 USPATFULL
TITLE:	Use of estrogen antagonists and estrogen agonists in inhibiting ~~pathological~~ conditions
INVENTOR(S):	Maclean, David B., Providence, RI, United States Thompson, David D., Gales Ferry, CT, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018451	A1	20010830
	US 6403611	B2	20020611
APPLICATION INFO.:	US 2001-803516	A1	20010309 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-314758, filed on 19 May 1999, PENDING Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, GRANTED, Pat. No. US

Searched by Barb O'Bryen, STIC 308-4291

6107331

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13212P	19960228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Paul H. Ginsburg, Pfizer Inc, 20th Floor, 235 East 42nd Street, New York, NY, 10017-5755	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2063	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0 180916-16-9**
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 30 OF 35 USPATFULL
ACCESSION NUMBER: 2001:131333 USPATFULL
TITLE: Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S): MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274618	B1	20010814
APPLICATION INFO.:	US 1999-314758		19990519 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-803733, filed on 21 Feb 1997, now patented, Pat. No. US 6107331

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-13212P	19960228 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Jones, Dwayne C.
ASSISTANT EXAMINER: Delacroix-Muirheid, C.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Donahue, E. Victor
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
LINE COUNT: 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180915-78-0 180916-16-9**
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)
RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-

pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 31 OF 35 USPATFULL
ACCESSION NUMBER: 2001:40500 USPATFULL
TITLE: Estrogen agonists/antagonists
INVENTOR(S): Cameron, Kimberly O., East Lyme, CT, United States
DaSilva Jardine, Paul A., Providence, RI, United States
Rosati, Robert L., Stonington, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:	US 6204286	B1	20010320
	WO 9621656		19960718
APPLICATION INFO.:	US 1997-849726		19970630 (8)
	WO 1995-IB286		19950424
			19970630 PCT 371 date
			19970630 PCT 102(e) date
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Qazi, Sabiha N.		
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1396		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula: ##STR1##

are disclosed useful for ~~treating~~ osteoporosis, obesity, breast cancer, endometriosis, cardiovascular disease and prostatic disease. Substituents A, B, E, D, Z1, G, Y and e have the same meaning as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**

(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



L35 ANSWER 32 OF 35 USPATFULL
ACCESSION NUMBER: 2000:161019 USPATFULL
TITLE: Estrogen agonists/antagonists
INVENTOR(S): ~~Cameron, Kimberly O., East Lyme~~, CT, United States
Dasilva-Jardine, Paul A., Providence, RI, United States
Ke, Hua Zhu, Ledyard, CT, United States
Rosati, Robert L., Stonington, CT, United States
PATENT ASSIGNEE(S): Pfizer, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6153622		20001128
APPLICATION INFO.:	US 1998-141613		19980828 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 849726		

Searched by Barb O'Bryen, STIC 308-4291

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1995-IB286	19950424
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Davis, Zinna Northington	
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1615	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



L35 ANSWER 33 OF 35 USPATFULL
ACCESSION NUMBER: 2000:109836 USPATFULL
TITLE: Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
INVENTOR(S): MacLean, David B., Providence, RI, United States
Thompson, David D., Gales Ferry, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6107331		20000822
APPLICATION INFO.:	US 1997-803733		19970221 (8)

NUMBER DATE

Searched by Barb O'Bryen, STIC 308-4291

PRIORITY INFORMATION:	US 1996-13212P 19960228 (60)
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Goldberg, Jerome D.
LEGAL REPRESENTATIVE:	Richardson, Peter C., Ginsburg, Paul H., Donahue, E. Victor
NUMBER OF CLAIMS:	1
EXEMPLARY CLAIM:	1
LINE COUNT:	1927

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0 180916-16-9**
(estrogen antagonists and estrogen agonists in inhibiting pathol. conditions)

RN 180915-78-0 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180916-16-9 USPATFULL

CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L35 ANSWER 34 OF 35 USPATFULL

ACCESSION NUMBER:	1999:106485 USPATFULL
TITLE:	(-) cis-6(S)-phenyl-5(R)[4-(2-pyrrolidin-1-yl ethoxy) phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol-D-tartrate
INVENTOR(S):	Chiu, Charles K., Attleboro, MA, United States Meltz, Morgan, Niantic, CT, United States
PATENT ASSIGNEE(S):	Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5948809		19990907	
	WO 9716434		19970509	
APPLICATION INFO.:	US 1998-65094		19980428	(9)
	WO 1996-IB1049		19961004	
			19980428	PCT 371 date
			19980428	PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-6125P	19951102 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Richter, Johann
ASSISTANT EXAMINER:	Oswecki, Jane C.
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Brokke, Mervin E.
NUMBER OF CLAIMS:	10
EXEMPLARY CLAIM:	1
LINE COUNT:	447

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB (-)Cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-1-yl ethoxy)phenyl]-5,6,7,8-tetrahydro-naphthalen-2-ol D-tartrate, pharmaceutical compositions comprising this compound, and an advantageous process for preparing the compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **180915-78-0P 180915-90-6P**
(prepn. of (-)-cis-(5R,6S)-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydro naphthalen-2-ol D-tartrate by optical resoln. for disease treatment)

RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT **190791-29-8P**
(prepn. of (-)-cis-(5R,6S)-phenyl[(pyrrolidinylethoxy)phenyl]tetrahydronaphthalen-2-ol D-tartrate by optical resoln. for disease treatment)
RN 190791-29-8 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 180916-16-9
CMF C28 H31 N O2

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6
CDES 1:S2:R*,R*

Absolute stereochemistry.



L35 ANSWER 35 OF 35 USPATFULL
ACCESSION NUMBER: 96:80279 USPATFULL
TITLE: 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
INVENTOR(S): Cameron, Kimberly O., Groton, CT, United States
Dasilva Jardine, Paul A., Groton, CT, United States
Rosati, Robert L., Groton, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5552412		19960903	
APPLICATION INFO.:	US 1995-369954		19950109	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Davis, Zinna Northington			
LEGAL REPRESENTATIVE:	Richardson, Peter C., Benson, Gregg C., Brokke, Mervin			

E.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 1358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of this formula ##STR1## are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **180915-78-0P 180915-79-1P 180915-85-9P 180915-90-6P 180915-91-7P 180915-93-9P 180916-16-9P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180915-78-0 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-79-1 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-85-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



● HCl

RN 180915-90-6 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-91-7 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 180915-93-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5S,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 180916-16-9 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, (5R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT **180916-11-4P**
(prepn. of 5-[4-(2-heterocyclylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalene-2-ols and 1-[4-(2-heterocyclylethoxy)phenyl]-6-hydroxy-1,2,3,4-tetrahydroisoquinolines as estrogen agonists/antagonists)
RN 180916-11-4 USPATFULL
CN 2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, cis-, compd. with (R)-4-hydroxydinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin 4-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 180915-78-0

CMF C28 H31 N O2
CDES 2:CIS

Relative stereochemistry.



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P
CDES 1:R



```
=> fil reg; d stat que l2
FILE 'REGISTRY' ENTERED AT 09:13:26 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   27 MAY 2003  HIGHEST RN 521262-77-1
DICTIONARY FILE UPDATES:  27 MAY 2003  HIGHEST RN 521262-77-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf


L1                STR
```



same full file search

```
VAR G1=CH2/N
VAR G2=CH/N
REP G3=(0-2) C
VPA 18-1/2/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L2            98 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 548752 ITERATIONS                      98 ANSWERS
SEARCH TIME: 00.00.15
```

```
=> fil capl; d que nos l30; s l30 not l19

FILE 'CAPLUS' ENTERED AT 09:13:27 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 28 May 2003  VOL 138 ISS 22
FILE LAST UPDATED: 27 May 2003  (20030527/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


L1              STR
L2           98 SEA FILE=REGISTRY SSS FUL L1
L14      263709 SEA FILE=CAPLUS ABB=ON  NEOPLASM#/CW
L15      155292 SEA FILE=CAPLUS ABB=ON  ANTITUMOR AGENTS+OLD/CT
L16       74700 SEA FILE=CAPLUS ABB=ON  CARCINOMA#/OBI
L17        6794 SEA FILE=CAPLUS ABB=ON  GLIOMA#/OBI
L18          34 SEA FILE=CAPLUS ABB=ON  DESMOID TUMOR#/OBI
L29          93 SEA FILE=CAPLUS ABB=ON  L2
L30          21 SEA FILE=CAPLUS ABB=ON  L29 AND (L14 OR L15 OR L16 OR L17 OR
                L18)


L36           6 L30 NOT L19
```

previously printed

```
=> fil uspatf; d que nos l32; s l32 not l27

FILE 'USPATFULL' ENTERED AT 09:13:28 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 May 2003 (20030527/PD)
FILE LAST UPDATED: 27 May 2003 (20030527/ED)
HIGHEST GRANTED PATENT NUMBER: US6571393
HIGHEST APPLICATION PUBLICATION NUMBER: US2003097700
CA INDEXING IS CURRENT THROUGH 27 May 2003 (20030527/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 May 2003 (20030527/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

>>>  USPAT2 is now available.  USPATFULL contains full text of the     <<<
>>>  original, i.e., the earliest published granted patents or         <<<
>>>  applications.  USPAT2 contains full text of the latest US         <<<
>>>  publications, starting in 2001, for the inventions covered in     <<<
>>>  USPATFULL.  A USPATFULL record contains not only the original     <<<
>>>  published document but also a list of any subsequent              <<<
>>>  publications.  The publication number, patent kind code, and      <<<
```

```
>>>  publication date for all the US publications for an invention     <<<
>>>  are displayed in the PI (Patent Information) field of USPATFULL   <<<
>>>  records and may be searched in standard search fields, e.g., /PN, <<<
>>>  /PK, etc.                                                         <<<

>>>  USPATFULL and USPAT2 can be accessed and searched together        <<<
>>>  through the new cluster USPATALL.  Type FILE USPATALL to          <<<
>>>  enter this cluster.                                               <<<
>>>                                                                    <<<
>>>  Use USPATALL when searching terms such as patent assignees,       <<<
>>>  classifications, or claims, that may potentially change from      <<<
>>>  the earliest to the latest publication.                           <<<

This file contains CAS Registry Numbers for easy and accurate
substance identification.


L1              STR
L2           98 SEA FILE=REGISTRY SSS FUL L1
L21       18110 SEA FILE=USPATFULL ABB=ON  NEOPLASM#/IT
L22        3248 SEA FILE=USPATFULL ABB=ON  CARCINOMA#/IT
L23         416 SEA FILE=USPATFULL ABB=ON  GLIOMA#/IT
L24           1 SEA FILE=USPATFULL ABB=ON  DESMOID/IT
L25        9868 SEA FILE=USPATFULL ABB=ON  ANTITUMOR AGENTS/CT
L26        8516 SEA FILE=USPATFULL ABB=ON  NEOPLASM INHIBITORS/CT
L31          80 SEA FILE=USPATFULL ABB=ON  L2
L32          21 SEA FILE=USPATFULL ABB=ON  (L21 OR L22 OR L23 OR L24 OR L25 OR
                L26) AND L31


L37           1 L32 NOT L27   previously printed

=> dup rem l36,l37
FILE 'CAPLUS' ENTERED AT 09:13:36 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 09:13:36 ON 28 MAY 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L36
PROCESSING COMPLETED FOR L37
L38            7 DUP REM L36 L37 (0 DUPLICATES REMOVED)
                 ANSWERS '1-6' FROM FILE CAPLUS
                 ANSWER '7' FROM FILE USPATFULL

=> d ibib abs hitstr l38 1-7; fil cao; d que nos l33; fil hom

L38  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2003:154395  CAPLUS
DOCUMENT NUMBER:          138:204820
TITLE:                    Preparation of triphenylethylene derivatives as
                          selective estrogen receptor modulators
INVENTOR(S):              Kaltenbach, Robert; Robinson, Simon; Trainor, George
PATENT ASSIGNEE(S):       Bristol-Myers Squibb Pharma Company, USA
SOURCE:                   PCT Int. Appl., 90 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016270	A2	20030227	WO 2002-US25394	20020809

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-311466P P 20010811

OTHER SOURCE(S): MARPAT 138:204820

GI



I

AB The present invention provides, inter alia, triphenylethylene derivs., (shown as I; variables defined below; e.g. 3-(4-[6-(3-methoxyphenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]phenyl)acrylic acid), as selective estrogen receptor modulators (no data). Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compns. of I. For I: R1 = C(O)XR6, 1-R7tetrazol-5-yl, C(O)NHSO2R8; R2 = H, C1-8 alkyl and halo; R3 = H, C1-8 alkyl, C1-8 alkylenyl, halo, or CN; alternatively R2 and R3, together with the atoms to which they are attached, form a six- or seven-membered ring structure where .gtoreq.1 of the atoms forming the ring may be O; R4 = H, OH, C1-8 alkyl, OC1-8 alkyl and halo; R5 = H, OH, CN, nitro, C1-8 alkyl, OC1-8 alkyl and halo; R6 = H, OH, CN, OC1-8 alkyl, Me, Et, Pr and Bu; R7 = H, aryl, C1-8 alkyl, OH, and OC1-8 alkyl; R8 = aryl, C1-8 alkyl, OH, and OC1-8 alkyl, wherein said R8 is optionally substituted with 1 to 2 substituents = halo, nitro, OH, CN, C1-4 alkyl, OC1-4alkyl, NH2, and NHC(O)OCMe3; X = O or NH, wherein when X is O, R6 is other than OH; and the broken line = an optional double bond. Although the methods of prepn. are not claimed, 76 example prepns. are included.

IT **248956-31-2P**, (E)-3-[4-(cis-6-Hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl]acrylic acid
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(drug candidate, chromatog. resoln.; prepn. of triphenylethylene derivs. as selective estrogen receptor modulators with therapeutic uses)

RN 248956-31-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



IT **500108-40-7P**, (E)-3-[4-((1R,2S)-6-Hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl]acrylic acid **500108-41-8P**, (E)-3-[4-((1S,2R)-6-Hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl)phenyl]acrylic acid
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of triphenylethylene derivs. as selective estrogen receptor modulators with therapeutic uses)

RN 500108-40-7 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 500108-41-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1S,2R)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



L38 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:449656 CAPLUS
DOCUMENT NUMBER: 137:47127
TITLE: Preparation of isoquinolines and isoindolines as selective estrogen receptor-.beta. ligand
INVENTOR(S): Barlaam, Bernard; Dantzman, Cathy
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046164	A1	20020613	WO 2001-SE2724	20011207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002022853	A5	20020618	AU 2002-22853	20011207

PRIORITY APPLN. INFO.:

US 2000-251775P	P	20001207
US 2000-251779P	P	20001207
SE 2001-6	A	20010102
SE 2001-7	A	20010102
WO 2001-SE2724	W	20011207

OTHER SOURCE(S): MARPAT 137:47127
GI



I



II

AB Title compds. I [R1 = H, (un)substituted-alkyl, -Ph, or -R10; R2 = (un)substituted-alkyl, -Ph, -PhCO, -benzyl or -R10; R3 = H, alkyl, Ph(CH2)m or R10(CH2)m; R4 = R3, halo; R5 and R8 independently = halo, CN, nitro, haloalkyl, R11, R11O, R11S, R112N, R11O2C, R11C(=O)O, R112NCO, R11COR11N, unsubstituted alkyl, etc.; R6 and R7 independently = halo, CN, nitro, haloalkyl, R11, R11O, R11S, R112N, R11O2C, R11C(=O)O, R112NCO, R11COR11N, etc. ; R10 = (un)substituted 5 or 6-membered heterocycle possessing 0-1 oxo groups and/or 0-1 fused benzo rings; R11 = H, alkyl, haloalkyl, Ph or benzyl; m = 0-3; n = 0-1] are prepd. and claimed, with their pharmaceutically acceptable salts, as selective estrogen receptor-.beta. ligands. Thus, II was prepd. by N-arylation of 6-methoxy-1,2,3,4-tetrahydroisoquinoline with 4-bromo-3-chloroanisole with subsequent boron tribromide deetherification. In estrogen receptor binding assays, I demonstrated Ki values for .beta.-ER in the range of 1.2-459 (nM). As selective ER-.beta. ligands, I are useful in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer.

IT **436856-43-8P 436856-45-0P 436856-47-2P**
436856-49-4P 436856-51-8P 436856-53-0P
436856-55-2P 436856-71-2P 436856-81-4P
436857-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of isoquinolines and isoindolines as selective estrogen receptor-.beta. ligands)

RN 436856-43-8 CAPLUS
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)



RN 436856-45-0 CAPLUS
CN 6-Isoquinolinol, 1-(2,4-dimethylphenyl)-1,2,3,4-tetrahydro-2-(4-

hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 436856-47-2 CAPLUS
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-1-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)



RN 436856-49-4 CAPLUS
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-1-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 436856-51-8 CAPLUS
CN 6-Isoquinolinol, 1-(2,4-dichlorophenyl)-1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



RN 436856-53-0 CAPLUS
CN 6-Isoquinolinol, 1-(4-ethylphenyl)-1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-(9CI) (CA INDEX NAME)



RN 436856-55-2 CAPLUS
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(4-hydroxyphenyl)-1-(2-methylphenyl)-(9CI) (CA INDEX NAME)



RN 436856-71-2 CAPLUS
CN 6-Isoquinolinol, 1,2,3,4-tetrahydro-2-(3-hydroxy-4-methylphenyl)-1-phenyl-(9CI) (CA INDEX NAME)



RN 436856-81-4 CAPLUS
CN 1H-Isoindol-5-ol, 2,3-dihydro-2-(4-hydroxyphenyl)-3-phenyl- (9CI) (CA INDEX NAME)



RN 436857-48-6 CAPLUS
CN 1H-Isoindol-5-ol, 2,3-dihydro-2-(4-hydroxyphenyl)-1-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:722743 CAPLUS
DOCUMENT NUMBER: 131:322428
TITLE: Dihydro- or tetrahydronaphthalene derivatives having estrogenic or antiestrogenic activity
INVENTOR(S): Nique, Francois
PATENT ASSIGNEE(S): Hoechst Marion Roussel, Fr.
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 955286	A1	19991110	EP 1999-401091	19990505
EP 955286	B1	20020807		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
FR 2778404	A1	19991112	FR 1998-5709	19980506
FR 2778404	B1	20000630		
US 6005003	A	19991221	US 1999-305620	19990505
AT 221870	E	20020815	AT 1999-401091	19990505
ES 2181372	T3	20030216	ES 1999-401091	19990505
JP 11349527	A2	19991221	JP 1999-125846	19990506

PRIORITY APPLN. INFO.: FR 1998-5709 A 19980506
OTHER SOURCE(S): MARPAT 131:322428
GI



I



II

AB Title compds. I and their prepn., intermediates, use, and pharmaceutical compns. are disclosed [wherein R1 = H, alkyl, acyl; R2, R3 = H, alkyl; or R2R3 = atoms to form cycloalkyl ring; R4 = aryl, heteroaryl; X = O, CH2; Y = OH, alkoxy, (un)substituted NH2]. I possess estrogenic, antiestrogenic, and antiproliferative activities, and are useful in the treatment of estrogen-related conditions, particularly osteoporosis, as well as estrogen-dependent cancers such as breast tumors. Examples include synthesis of 32 invention compds. and bioassays of 3 compds. For instance, 2-(4-bromophenyl)-1,3-dioxolane was lithiated, treated with CeCl3, and coupled with 3,4-dihydro-6-methoxy-1(2H)-naphthalenone, followed by bromination at the naphthalene 2-position, arylation of the bromide with PhB(OH)2, Wittig reaction with Ph3P:CHCO2Et, demethylation of the methoxy group, and alk. sapon. of the ester, to give title compd. II. The latter compd. bound to human estrogen receptors in vitro with 72% of the affinity of estradiol. II also inhibited the growth of MCF-7 breast tumor cells in vitro.

IT **248956-30-1P 248956-31-2P 248956-33-4P**
248956-41-4P 248956-43-6P 248956-45-8P
248956-53-8P 248956-54-9P 248956-57-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of di- and tetrahydronaphthalene derivs. as estrogens and antiestrogens)

RN 248956-30-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-31-2 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-33-4 CAPLUS
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-41-4 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-43-6 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-45-8 CAPLUS
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-53-8 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-54-9 CAPLUS
CN 2-Propenoic acid, 3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-57-2 CAPLUS
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1991:449032 CAPLUS
DOCUMENT NUMBER: 115:49032
TITLE: Synthesis and biological behavior of a boronated analog of the antiestrogen U 23,469-M
AUTHOR(S): Wellmann, Folkert; Abraham, Ralph; Mueller, Rainer; Gabel, Detlef
CORPORATE SOURCE: Fachbereich Chem., Univ. Bremen, Bremen, D-2800/33, Germany
SOURCE: Zeitschrift fuer Naturforschung, C: Journal of Biosciences (1991), 46(3-4), 252-6
CODEN: ZNCBDA; ISSN: 0341-0382
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The title compd. I (R = decachloro-o-carboranyl) was prepd., for possible use in neutron capture therapy of estrogen receptor-pos. tumors. This compd. showed a large, non-specific uptake in ZR 75-1 breast cancer-derived cells. It partially inhibited the uptake of estradiol in these cells. Accumulation in the cells at physiol. obtainable concns. was, however, too low to envisage a therapeutic effect following thermal neutron irradn.

IT **98537-27-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and radio-sensitizing antitumor activity of)
RN 98537-27-0 CAPLUS
CN 1,2-Dicarbadodecaborane(12)-1-ethanol, 3,4,5,6,7,8,9,10,11,12-decachloro-.alpha.-[[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L38 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1982:97932 CAPLUS
DOCUMENT NUMBER: 96:97932
TITLE: Effects of estrogens and antiestrogens on estrogen receptor dynamics and the induction of progesterone receptor in MCF-7 human breast cancer cells
AUTHOR(S): Eckert, Richard L.; Katzenellenbogen, Benita S.
CORPORATE SOURCE: Dep. Physiol. Biophys., Univ. Illinois, Urbana, IL, 61801, USA
SOURCE: Cancer Research (1982), 42(1), 139-44
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The effects of the estrogens estradiol [50-28-2] and diethylstilbestrol [56-53-1] and the triphenylethylene antiestrogens CI628 [5863-35-4], CI628M [76313-96-7], U23,469 [36840-93-4], and U23,469M [**72105-61-4**] on intracellular estrogen receptor (ER) dynamics and growth and progesterone [57-83-0] receptor induction were examd. in MCF-7

human breast cancer cells. The relative binding affinities of the antiestrogens for cytoplasmic ER (ERC) were 1.0, 17, 0.04, and 34%, resp., in which the affinity of estradiol is considered 100%. Receptor-satg. concns. of CI628, CI628M, estradiol, and diethylstilbestrol (200, 10, 10, and 10 nM, resp.) caused complete ERC depletion and peak nuclear ER accumulation within 1 h. The nuclear receptor (ERN) sites declined thereafter and stabilized at near-control levels (1.2 pmol ERN/mg DNA) by 2-5 h, resulting in a net loss (processing) of approx. 50% of total cellular ER. In contrast, U23,469 (2000 nM) promoted complete depletion of ERC and quant. accumulation as ERN with 5 min, but the total ER content remained const. thereafter (no processing). U23,469M (60 nM) promoted complete ERC depletion and quant. nuclear accumulation, but the no. of ERN sites subsequently declined slowly to reach the control level by Day 5. Among these compds., estradiol and diethylstilbestrol (0.1-1000 nM) promoted a 600% increase in cytoplasmic progesterone receptor (5 days, control = 0.2 pmol/mg DNA). CI628M and U23,469M (1-10 nM) produced only a 300% increase, and U23,469 and CI628 (0.1-1000 nM) did not promote any increase. ER translocation to the nucleus and progesterone receptor induction appear to be related to ligand affinity. Antiestrogens differ substantially from one another in their dynamics of interaction with ER and in their abilities to stimulate increases in cellular progesterone receptor. Processing of ER by antiestrogens such as CI628 does not ensure subsequent induction of progesterone receptor; and an apparently complex relation exists between the presence and duration of hormone receptor complexes in the nucleus and the induction of progesterone receptor in MCF-7 cells. Since all 4 antiestrogens inhibit MCF-7 cell growth but differ in their ability to increase cellular progesterone receptor levels, these studies indicate that growth and progesterone receptor induction are phenomena that are independently modulated by antiestrogens in these human breast cancer cells.

IT **72105-61-4**
RL: BIOL (Biological study)
(estrogen and progesterone receptors of cytoplasm and nucleus of human mammary cancer cells response to)

RN 72105-61-4 CAPLUS
CN 1,2-Propanediol, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]- (9CI) (CA INDEX NAME)



L38 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1981:202868 CAPLUS
DOCUMENT NUMBER: 94:202868
TITLE: Antitumor activities and estrogen receptor interactions of the metabolites of the antiestrogens CI628 and U23,469 in the 7,12-dimethylbenz(a)anthracene-induced rat mammary tumor system
AUTHOR(S): Rorke, Ellen A.; Katzenellenbogen, Benita S.

Searched by Barb O'Bryen, STIC 308-4291

CORPORATE SOURCE: Sch. Basic. Med. Sci., Univ. Illinois, Urbana, IL, 61801, USA
SOURCE: Cancer Research (1981), 41(4), 1257-62
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The antitumor activities of the nonsteroidal antiestrogens .alpha.-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-methoxy-.alpha.'-nitrostilbene (C1628) [10448-84-7] and cis-{3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol} (U23,469) [36840-93-4] are compared with their demethylated metabolite forms in the dimethylbenz(a)anthracene-induced rat mammary tumor system. These demethylated forms are generated in vivo and are selectively accumulated in the nuclear estrogen receptor fraction in preference to the parent compd.; thus, direct administration of the metabolites was investigated for eliciting tumor regression. The potencies of the parent antiestrogens and their demethylated forms .alpha.-{p-[2-(1-pyrrolidino)ethoxy]phenyl}-4-hydroxy-.alpha.'-nitrostilbene (CI628M) [76313-96-7] and cis-{3-[p-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthyl)-phenoxy]-1,2-propanediol} (U23,469M) [**72105-61-4**] were examd. for stimulating the regression of establishing dimethylbenz(a)anthracene-induced mammary tumors. The effects of these antiestrogens on estrogen receptors and peroxidase [9003-99-0] as a sp. marker for estrogen action in mammary tumors and in uteri of tumor-bearing animals were also monitored. In mammary tumor cytosol in vitro, the antiestrogens completed with [3H]estradiol for binding to estrogen receptor with affinities of 113% (CI628M), 5% (CI628), 31% (U23,469M), and 0.6% (U23,469), where the affinity of estradiol is considered to be 100%. All 4 antiestrogens were equally effective as antagonists of tumor growth in vivo. Administration of 25 or 100 .mu.g daily of either parent (CI628 and U23,469) or the demethylated (CI628M and U23,469M) antiestrogens elicited the regression of the majority of dimethylbenz(a)anthracene tumors, whereas low doses (2.5 .mu.g/day) of any of these 4 compds. had no effect on tumor growth. The 25- and 100-.mu.g doses of antiestrogens markedly reduced tumor cytoplasmic estrogen receptor levels, but they failed to elevate tumor peroxidase activity. Uterine wts. were decreased below the diestrus controls following treatment with 25- or 100-.mu.g daily doses of the antiestrogens; these treatments also resulted in the nuclear localization of .apprx.80% of the total estrogen receptors. Uterine peroxidase activity, which was high in diestrus control females, was reduced to 5-25% by the intermediate- or high-dose levels of antiestrogens. Although the demethylated antiestrogens have a 20-50-fold enhanced affinity for the mammary tumor estrogen receptor in vitro as compared to their parent compd. in vivo, where the parent compds. are rapidly converted to the demethylated metabolites, both forms are equally potent antitumor and antiuterotropic agents.

IT **72105-61-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neoplasm-inhibiting activity of, estrogen receptor interactions in relation to)
RN 72105-61-4 CAPLUS
CN 1,2-Propanediol, 3-[4-(1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl)phenoxy]- (9CI) (CA INDEX NAME)



L38 ANSWER 7 OF 7 USPATFULL

ACCESSION NUMBER:	1999:167043 USPATFULL		
TITLE:	Derivatives of dihydro or tetrahydronaphthalene, and the pharmaceutical compositions containing them		
INVENTOR(S):	Nique, Francois, Le Perreux sur Marne, France		
PATENT ASSIGNEE(S):	Hoechst Marion Roussel, France (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6005003		19991221
APPLICATION INFO.:	US 1999-305620		19990505 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	FR 1998-5709		19980506
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Gerstl, Robert		
LEGAL REPRESENTATIVE:	Bierman, Muserlian and Lucas		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1008		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A subject of the invention is the compounds of general formula (I): ##STR1## in which R1=H, alkyl, acyl, R2 and R3=H, alkyl, R4=aryl, heteroaryl, X=O, CH2, Y=OH, O-alkyl or NRaRb, as well as the salts, their preparation processes, the intermediates of these processes, their use as medicaments and the pharmaceutical compositions containing them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **248956-30-1P 248956-31-2P 248956-33-4P**
248956-41-4P 248956-43-6P 248956-45-8P
248956-53-8P 248956-54-9P 248956-57-2P
(target compd.; prepn. of di- and tetrahydronaphthalene derivs. as estrogens and antiestrogens)

RN 248956-30-1 USPATFULL

CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-31-2 USPATFULL
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-33-4 USPATFULL
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-phenyl-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-41-4 USPATFULL
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-43-6 USPATFULL
CN 2-Propenoic acid, 3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-45-8 USPATFULL
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-1,2,3,4-tetrahydro-6-hydroxy-2-(4-hydroxyphenyl)-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-53-8 USPATFULL
CN 2-Propenoic acid, 3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, ethyl ester, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-54-9 USPATFULL
CN 2-Propenoic acid, 3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



RN 248956-57-2 USPATFULL
CN 2-Propenamide, N,N-diethyl-3-[4-[(1R,2S)-2-(4-fluorophenyl)-1,2,3,4-tetrahydro-6-hydroxy-1-naphthalenyl]phenyl]-, (2E)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.
Double bond geometry as shown.



FILE 'CAOLD' ENTERED AT 09:13:55 ON 28 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L1             STR
L2            98 SEA FILE=REGISTRY SSS FUL L1
L33            0 SEA FILE=CAOLD ABB=ON  L2
```

FILE 'HOME' ENTERED AT 09:13:55 ON 28 MAY 2003